Using Doppler endoscopic probe to diagnose gastrointestinal lesions
Role of Doppler Endoscopic Probe in the Diagnosis of Subepithelial Gastrointestinal Lesions.
This study is testing whether a special Doppler endoscopic probe can help doctors better diagnose certain types of growths in the upper digestive tract.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Karolinska University Hospital Academic / other |
| Locations | 1 site (Stockholm) |
| Trial ID | NCT05983406 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of a Doppler endoscopic probe in diagnosing subepithelial lesions (SELs) in the upper gastrointestinal tract. SELs are often detected during routine endoscopies, but traditional methods like endoscopic ultrasound (EUS) have limitations in providing definitive diagnoses. The study aims to improve diagnostic accuracy and management of these lesions by utilizing Doppler technology, which may enhance the characterization of vascular involvement. Participants will undergo Doppler investigations to assess the potential benefits of this approach compared to standard methods.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals with detected subepithelial lesions in the gastrointestinal tract.
Not a fit: Patients on anticoagulation therapy that cannot be discontinued, those with liver cirrhosis and coagulopathy, or individuals with malignancy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate diagnoses of subepithelial gastrointestinal lesions, improving patient management and outcomes.
How similar studies have performed: While traditional methods like EUS have been widely used, the application of Doppler technology in this context is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Presence of subepithelial lesion on the GI tract. Exclusion Criteria: * Anticoagulation therapy that cannot be discontinued * Liver cirrhosis with coagulopathy or varices * Malignancy
Where this trial is running
Stockholm
- Karolinska University Hospital & Karolinska Institute — Stockholm, Sweden (Recruiting)
Study contacts
- Study coordinator: Francisco Baldaque-Silva, MD PhD
- Email: fbaldaquesilva@gmail.com
- Phone: +46704997219
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.